ArticleImmunotherapy2024
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China.
Xinyi Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
ArticleImmunotherapy2024
Xinyi Xu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.